Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $43.42 in the prior trading day, Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) closed at $42.27, down -2.65%. In other words, the price has decreased by -$2.65 from its previous closing price. On the day, 0.77 million shares were traded. RARE stock price reached its highest trading level at $43.82 during the session, while it also had its lowest trading level at $41.53.
Ratios:
Our goal is to gain a better understanding of RARE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.65 and its Current Ratio is at 2.81. In the meantime, Its Debt-to-Equity ratio is 2.63 whereas as Long-Term Debt/Eq ratio is at 2.46.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on June 06, 2024, Upgraded its rating to Buy and sets its target price to $67 from $56 previously.
On April 22, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $77.
On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $72.Wells Fargo initiated its Overweight rating on December 08, 2023, with a $72 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 30 ’24 when KAKKIS EMIL D bought 11,727 shares for $42.23 per share.
KAKKIS EMIL D sold 8,273 shares of RARE for $413,650 on Dec 10 ’24. The President & CEO now owns 2,195,712 shares after completing the transaction at $50.00 per share. On Dec 10 ’24, another insider, KAKKIS EMIL D, who serves as the Officer of the company, bought 8,273 shares for $50.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 3903393792 and an Enterprise Value of 4212468736. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.40 while its Price-to-Book (P/B) ratio in mrq is 11.24. Its current Enterprise Value per Revenue stands at 8.058 whereas that against EBITDA is -8.407.
Stock Price History:
Over the past 52 weeks, RARE has reached a high of $60.37, while it has fallen to a 52-week low of $37.02. The 50-Day Moving Average of the stock is -12.58%, while the 200-Day Moving Average is calculated to be -11.46%.
Shares Statistics:
The stock has traded on average 758.16K shares per day over the past 3-months and 902760 shares per day over the last 10 days, according to various share statistics. A total of 92.24M shares are outstanding, with a floating share count of 83.35M. Insiders hold about 9.74% of the company’s shares, while institutions hold 92.11% stake in the company. Shares short for RARE as of 1734048000 were 3713992 with a Short Ratio of 4.90, compared to 1731628800 on 3346228. Therefore, it implies a Short% of Shares Outstanding of 3713992 and a Short% of Float of 4.61.
